Hair depigmentation in a patient treated with pazopanib: A case report and a comprehensive analysis

Abstract

Pazopanib is a multitargeted tyrosine kinase inhibitor used for the treatment of various solid tumor malignancies. Hair color change, particularly hair depigmentation, is a common side effect of pazopanib therapy. However, it usually develops gradually over a span of few months. This article will provide a comprehensive analysis of hair depigmentation in patients treated with pazopanib, focusing on the various aspects of this phenomenon, including its onset, possible causes, and potential implications for therapy success. Multitargeted tyrosine kinase inhibitors (MKIs) including pazopanib are recommended for various malignancies. Hair color changes are known side effects of MKIs. The exact mechanisms behind hair depigmentation due to pazopanib therapy are not yet fully understood. However, researchers believe that several factors may contribute to this phenomenon. We presented a case of a patient with relapse Ewings sarcoma who experienced rapid hair depigmentation during pazopanib therapy.